BioNTech (Mfg Services)

Mainz, DE · Marburg, DE
Find alternatives to BioNTech (Mfg Services) for mRNA →
Hybrid — also manufactures internal programs
28 confirmed programs · 11 sponsors · Last scored 2026-10-29
82.1
Signal Score
○ FDA Inspections ✓ Clinical Trials (28) ✓ SEC Filings (97) ○ Press ✓ EMA GMP (8) ○ MHRA GMP ✓ HC GMP (2)

Quick Facts: BioNTech (Mfg Services)

Signal Score
82.1/100 (as of 2026-10-29)
Quality Compliance
100.0/100 — Clean EMA record: 8 active GMP certificates (no deductions)
Headquarters
Mainz, DE · Marburg, DE
Modalities
mRNA
Active Programs
28 confirmed from ClinicalTrials.gov across 11 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About BioNTech (Mfg Services)

mRNA COVID vaccine manufacturer. Contract mfg capabilities.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Clean EMA record: 8 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Clean EMA record: 8 active GMP certificates (no deductions)
FDA InspectionsNo US records on file
EMA GMP Certificates8 on record
Most Recent HC OutcomeCompliant · 2024-01-25
HC Attribution2 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 8 active GMP certificates (no deductions)
Operations 75.5
28 active programs across 11 sponsors
Modalities: mRNA
21 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
28 active programs across 11 sponsors · Modalities: mRNA · 21 programs in advanced phases (Phase 2/3)
Programs 28
Sponsors11
ModalitiesmRNA
28 active programs across 11 sponsors
Modalities: mRNA
21 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07361497 A Study to Evaluate Pumitamig Versus Durvalumab Following... PHASE3 Recruiting
NCT07361510 A Study to Evaluate the Efficacy of Pumitamig Versus... PHASE3 Recruiting
NCT07111520 A Clinical Trial to Test if an Investigational Combination... PHASE1/PHASE2 Recruiting
NCT07070232 A Clinical Study to Test if an Investigational Treatment... PHASE1/PHASE2 Recruiting
NCT06953089 DB-1311 in Combination With BNT327 or DB-1305 in... PHASE2 Recruiting
NCT06940804 A Clinical Study Investigating the Therapeutic Effects and... PHASE2 Withdrawn
NCT06892548 A Clinical Study to Investigate the Efficacy and Safety of an... PHASE1/PHASE2 Recruiting
NCT06841055 Safety and Preliminary Efficacy of Pumitamig (BNT327), an... PHASE2 Recruiting
NCT06712355 Safety and Efficacy of BNT327, an Investigational Therapy in... PHASE3 Recruiting
NCT06750185 Safety and Preliminary Effectiveness of BNT317, an... PHASE1/PHASE2 Recruiting
View all 28 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
97 SEC filings with industry mentions on record (shown, not scored)
SEC Filings97 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity 58.0
3 manufacturing sites
Sites: Mainz, Germany, Marburg, Germany, Idar-Oberstein, Germany
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
3 manufacturing sites

BioNTech (Mfg Services) EMA GMP Compliance 8 certificates

2025-10
2025-10
2025-10
2025-10
2025-10
2025-06
2024-09
2019-09
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
DE_RP_01_GMP_2025_0049 BioNTech Innovative Manufacturing Services GmbH Germany 2025-10-23 COMPLIANT
DE_RP_01_GMP_2026_0018 BioNTech SE Germany 2025-10-01 COMPLIANT
DE_RP_01_GMP_2026_0004 BioNTech SE Germany 2025-10-01 COMPLIANT
DE_RP_01_GMP_2026_0007 BioNTech Manufacturing GmbH Germany 2025-10-01 COMPLIANT
DE_RP_01_GMP_2026_0025 BioNTech SE Germany 2025-10-01 COMPLIANT
DE_RP_01_GMP_2026_0006 BioNTech Manufacturing GmbH Germany 2025-06-17 COMPLIANT
DE_HE_01_GMP_2025_0030 BioNTech Manufacturing Marburg GmbH Germany 2024-09-04 COMPLIANT
DE_RP_01_GMP_2020_0052 BioNTech Manufacturing GmbH Germany 2019-09-11 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Clinical Activity 28 studies

NCT07361497 A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent... PHASE3 Recruiting NCT07361510 A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in... PHASE3 Recruiting NCT07111520 A Clinical Trial to Test if an Investigational Combination Therapy With... PHASE1/PHASE2 Recruiting NCT07070232 A Clinical Study to Test if an Investigational Treatment Called BNT326 is... PHASE1/PHASE2 Recruiting NCT06953089 DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors PHASE2 Recruiting NCT06940804 A Clinical Study Investigating the Therapeutic Effects and Safety of an... PHASE2 Withdrawn NCT06892548 A Clinical Study to Investigate the Efficacy and Safety of an... PHASE1/PHASE2 Recruiting NCT06841055 Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational... PHASE2 Recruiting NCT06712355 Safety and Efficacy of BNT327, an Investigational Therapy in Combination... PHASE3 Recruiting NCT06750185 Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy... PHASE1/PHASE2 Recruiting NCT06712316 Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With... PHASE2/PHASE3 Recruiting NCT06616532 PM8002 in Combination With Paclitaxel Compared With Chemotherapy as... PHASE3 Active Not Recruiting NCT06449209 Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for... PHASE2 Active Not Recruiting NCT06046274 GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced... PHASE2 Withdrawn NCT05914116 A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors PHASE1/PHASE2 Recruiting NCT05844150 A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in... PHASE2 Active Not Recruiting NCT05557591 A Trial to Learn How the Cancer Vaccine BNT116 in Combination With... PHASE2 Active Not Recruiting NCT05438329 First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors PHASE1/PHASE2 Active Not Recruiting NCT05142189 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy... PHASE1 Recruiting NCT05879068 A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC PHASE2 Active Not Recruiting
+ 8 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity Beta

From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No open roles were listed at this business's sites on Nov 20, 2026.
Coverage: read from the parent company's careers board and kept only postings at this business's sites (BioNTech Innovative Manufacturing Services (Idar-Oberstein) on the BioNTech-wide board). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: jobs.biontech.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Financial Intelligence

6-K 2026-10-26 0 keyword mentions
6-K 2026-10-26 0 keyword mentions
6-K 2026-10-22 0 keyword mentions
6-K 2026-10-19 0 keyword mentions
6-K 2026-10-13 0 keyword mentions
6-K 2026-09-18 0 keyword mentions
6-K 2026-09-14 0 keyword mentions
6-K 2026-08-28 0 keyword mentions
6-K 2026-08-27 0 keyword mentions
6-K 2026-08-20 0 keyword mentions
6-K 2026-08-04 0 keyword mentions
6-K 2026-08-04 0 keyword mentions
6-K 2026-08-03 0 keyword mentions
6-K 2026-07-29 0 keyword mentions
6-K 2026-06-08 0 keyword mentions
6-K 2026-06-01 0 keyword mentions
6-K 2026-05-22 0 keyword mentions
6-K 2026-05-15 0 keyword mentions
6-K 2026-05-07 0 keyword mentions
6-K 2026-05-05 0 keyword mentions
6-K 2026-05-05 0 keyword mentions
6-K 2026-04-13 0 keyword mentions
6-K 2026-04-02 0 keyword mentions
6-K 2026-03-24 0 keyword mentions
20-F 2026-03-10 54 keyword mentions
"gene therapy, that are perceived as similar to ours; and – the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology"
"candidates, such as gene editing therapies, show encouraging results, potential trial participants and their"
"such entities, which include locally-based contract manufacturing organizations, or CMOs, and CROs, in the"
6-K 2026-03-10 0 keyword mentions
6-K 2026-03-10 0 keyword mentions
6-K 2026-01-28 0 keyword mentions
6-K 2026-01-14 0 keyword mentions
6-K 2026-01-12 0 keyword mentions
6-K 2026-01-06 0 keyword mentions
6-K 2025-12-18 0 keyword mentions
6-K 2025-12-09 0 keyword mentions
6-K 2025-12-08 0 keyword mentions
6-K 2025-12-03 0 keyword mentions
6-K 2025-11-26 0 keyword mentions
6-K 2025-11-12 0 keyword mentions
6-K 2025-11-03 0 keyword mentions
6-K 2025-11-03 0 keyword mentions
6-K 2025-10-22 0 keyword mentions
6-K 2025-10-01 0 keyword mentions
6-K 2025-09-08 0 keyword mentions
6-K 2025-09-08 0 keyword mentions
6-K 2025-09-05 0 keyword mentions
6-K 2025-08-27 0 keyword mentions
6-K 2025-08-11 0 keyword mentions
6-K 2025-08-04 0 keyword mentions
6-K 2025-08-04 0 keyword mentions
6-K 2025-07-25 0 keyword mentions
6-K 2025-07-17 0 keyword mentions
6-K 2025-06-17 0 keyword mentions
6-K 2025-06-17 0 keyword mentions
6-K 2025-06-12 0 keyword mentions
6-K 2025-06-02 0 keyword mentions
6-K 2025-05-27 0 keyword mentions
6-K 2025-05-20 0 keyword mentions
6-K 2025-05-16 0 keyword mentions
6-K 2025-05-05 0 keyword mentions
6-K 2025-05-05 0 keyword mentions
6-K 2025-05-05 0 keyword mentions
6-K 2025-04-24 0 keyword mentions
6-K 2025-04-04 0 keyword mentions
6-K 2025-04-02 0 keyword mentions
20-F 2025-03-10 40 keyword mentions
"contract manufacturing production capacities that become redundant or unutilized; • our expected revenues and net profit related to sales of our COVID-19 vaccine (also referred to as"
"write-downs and cancellations of contract manufacturing orders."
"operations; • continue to invest in our immunotherapy platforms to conduct research to identify novel technologies; • change our manufacturing capacity or capability; • change or add additional suppliers; • make changes to our infrastructure in connection with our quality control, quality assurance, legal,"
6-K 2025-03-10 0 keyword mentions
6-K 2025-03-04 0 keyword mentions
6-K 2025-02-03 0 keyword mentions
6-K 2025-01-14 0 keyword mentions
6-K 2024-12-27 0 keyword mentions
6-K 2024-12-27 0 keyword mentions
6-K 2024-12-13 0 keyword mentions
6-K 2024-11-14 0 keyword mentions
6-K 2024-11-13 0 keyword mentions
6-K 2024-11-04 0 keyword mentions
6-K 2024-11-04 0 keyword mentions
6-K 2024-10-18 0 keyword mentions
6-K 2024-10-01 0 keyword mentions
6-K 2024-09-20 0 keyword mentions
6-K 2024-09-05 0 keyword mentions
6-K 2024-08-22 0 keyword mentions
6-K 2024-08-19 0 keyword mentions
6-K 2024-08-16 0 keyword mentions
6-K 2024-08-07 0 keyword mentions
6-K 2024-08-05 0 keyword mentions
6-K 2024-08-05 0 keyword mentions
6-K 2024-07-30 0 keyword mentions
6-K 2024-06-28 0 keyword mentions
6-K 2024-06-24 0 keyword mentions
6-K 2024-06-17 0 keyword mentions
6-K 2024-06-03 0 keyword mentions
6-K 2024-05-30 0 keyword mentions
6-K 2024-05-21 1 keyword mentions
"Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studies in patient populations for which product candidates are being developed in the Company’s respective clinical programs."
6-K 2024-05-17 0 keyword mentions
6-K 2024-05-06 0 keyword mentions
6-K 2024-05-06 0 keyword mentions
6-K 2024-04-08 0 keyword mentions
6-K 2024-04-08 0 keyword mentions
Source: SEC EDGAR · Retrieved Nov 21, 2026

Frequently Asked Questions About BioNTech (Mfg Services)

Does BioNTech (Mfg Services) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 8 EMA GMP certificates for BioNTech (Mfg Services).
How many clinical programs is BioNTech (Mfg Services) linked to?
BioNTech (Mfg Services) is associated with 28 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is BioNTech (Mfg Services)'s CDMO Signal Score?
BioNTech (Mfg Services) has a Signal Score of 82/100, based on quality, operations, financial stability, and capacity data.
Evaluating BioNTech (Mfg Services) for a manufacturing program?
Use the free AI matchmaker to compare BioNTech (Mfg Services) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →

Similar CDMOs

Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Signal Score: 82.9
Recombinant Protein, Plasmid DNA, mRNA, Microbial Fermentation

Compare BioNTech (Mfg Services) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on BioNTech (Mfg Services)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.